Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 4426 AL 4440

Alzheimer's disease: cerebrolysin and nanotechnology as a therapeutic strategy

Sharma HS, Muresanu DF, Sharma A.

Neurodegener Dis Manag. 2016 Dec;6(6):453-456. doi: 10.2217/nmt-2016-0037. Epub 2016 Nov 9.

The road to restoring neural circuits for the treatment of Alzheimer's disease

Canter RG, Penney J, Tsai LH.

Nature. 2016 Nov 10;539(7628):187-196. doi: 10.1038/nature20412.

The crisis in recruitment for clinical trials in Alzheimer's and dementia: An action plan for solutions

Fargo KN, Carrillo MC, Weiner MW, Potter WZ, Khachaturian Z.

Alzheimers Dement. 2016 Nov;12(11):1113-1115. doi: 10.1016/j.jalz.2016.10.001.

Pharmacological Effects of Active Components of Chinese Herbal Medicine in the Treatment of Alzheimer's Disease: A Review

Wang ZY, Liu JG, Li H, Yang HM.

Am J Chin Med. 2016;44(8):1525-1541. doi: 10.1142/S0192415X16500853. Epub 2016 Nov 16.

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Wischik DJ, Schelter BO, Davis CS, Staff RT, Bracoud L, Shamsi K, Storey JM, Harrington CR, Wischik CM.

Lancet. 2016 Dec 10;388(10062):2873-2884. doi: 10.1016/S0140-6736(16)31275-2. Epub 2016 Nov 16.

Human gut microbiota: the links with dementia development

Alkasir R, Li J, Li X, Jin M, Zhu B.

Protein Cell. 2017 Feb;8(2):90-102. doi: 10.1007/s13238-016-0338-6. Epub 2016 Nov 19.

Exercise Training for Persons with Alzheimer's Disease and Caregivers: A Review of Dyadic Exercise Interventions

Lamotte G, Shah RC, Lazarov O, Corcos DM.

J Mot Behav. 2017 Jul-Aug;49(4):365-377. doi: 10.1080/00222895.2016.1241739. Epub 2016 Nov 21.

A review on tacrine-based scaffolds as multi-target drugs (MTDLs) for Alzheimer's disease

Sameem B, Saeedi M, Mahdavi M, Shafiee A.

Eur J Med Chem. 2017 Mar 10;128:332-345. doi: 10.1016/j.ejmech.2016.10.060. Epub 2016 Oct 28.

Promise of new Alzheimer's drug is dashed after lack of evidence

Hawkes N.

BMJ. 2016 Nov 24;355:i6362. doi: 10.1136/bmj.i6362.

Pioglitazone for the treatment of Alzheimer's disease

Galimberti D, Scarpini E.

Expert Opin Investig Drugs. 2017 Jan;26(1):97-101. doi: 10.1080/13543784.2017.1265504. Epub 2016 Dec 4.

Nanotechnology-based drug delivery systems for Alzheimer's disease management: Technical, industrial, and clinical challenges

Wen MM, El-Salamouni NS, El-Refaie WM, Hazzah HA, Ali MM, Tosi G, Farid RM, Blanco-Prieto MJ, Billa N, Hanafy AS.

J Control Release. 2017 Jan 10;245:95-107. doi: 10.1016/j.jconrel.2016.11.025. Epub 2016 Nov 23.

Targeting Functional Decline in Alzheimer Disease: A Randomized Trial

Callahan CM, Boustani MA, Schmid AA, LaMantia MA, Austrom MG, Miller DK, Gao S, Ferguson DY, Lane KA, Hendrie HC.

Ann Intern Med. 2017 Feb 7;166(3):164-171. doi: 10.7326/M16-0830. Epub 2016 Nov 22.

Sixty seconds on . . . solanezumab

Hawkes N.

BMJ. 2016 Nov 29;355:i6389. doi: 10.1136/bmj.i6389.

Sex and gender differences in the treatment of Alzheimer's disease: A systematic review of randomized controlled trials

Canevelli M, Quarata F, Remiddi F, Lucchini F, Lacorte E, Vanacore N, Bruno G, Cesari M.

Pharmacol Res. 2017 Jan;115:218-223. doi: 10.1016/j.phrs.2016.11.035. Epub 2016 Nov 30.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias